DANVERS, Mass., Aug. 3 /PRNewswire-FirstCall/ -- Medwave, Inc. , the innovator in sensor-based, non-invasive blood pressure measuring solutions, announced today that it will deliver a presentation at the 26th Annual Canaccord Adams Summer Seminar in Boston. Tim O'Malley, President and CEO of Medwave, Inc., is scheduled to present to leading institutional investment representatives on Thursday, August 10, 2006, at the Boston Marriott Long Wharf Hotel.
"This year, we saw the release of a product that fundamentally changes the medical device landscape," said Tim O'Malley, President and CEO of Medwave, Inc. "We are excited to be able to share our growth story with investors worldwide."
Medwave's presentation will also be webcast live over the Internet. To access the audio presentation with viewer-driven slides live at 10:30 AM ET, please go to http://www.medwave.com , select Medwave The Company, and click on Investor Info, or type in this address directly to go straight to the page: http://www.medwave.com/medinvq.htm . Then click on the link titled "Medwave at Canaccord Adams 26th Annual Summer Seminar 2006". Replays of the webcast will also become available approximately one hour after the live webcast presentation ends.
"This seminar affords us the opportunity to share important information about our growth as a company," said Teresa Kalinowsky, VP of Finance of Medwave, Inc. "We will provide a mid-year update and discuss the latest additions to our sensor-based product suite, including our new Fusion(TM) product, which we hope to launch later this year."
"We feel that Medwave represents the very ideal of a rapid growth, publicly traded, medical technology company, and we are excited to have them present at this year's seminar," said Kevin Dunn, President and CEO of Canaccord Adams Inc.
The Canaccord Adams Annual Summer Seminar is one of the oldest and largest programs showcasing both publicly traded and privately held growth companies. Most of the presenting public companies are covered by Canaccord Adams' global team of equity analysts. To learn more about the conference, please contact Nadine Miller at 617.371.3842 or Nadine.Miller@CanaccordAdams.com.
About Canaccord Adams
Canaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, our 225 professionals seek out emerging opportunities in our key sectors - Mining and Metals, Energy, Technology, Life Sciences, Real Estate and Gaming, Consumer and Industrial Growth. Located in nine offices internationally, our experienced team generates focused, actionable ideas that identify opportunity and facilitate growth. More information is available at http://www.canaccordadams.com . Canaccord Adams Inc., Member NASD/SIPC.
About Medwave
Medwave, Inc. develops, manufactures and distributes sensor-based non- invasive blood pressure solutions. Medwave's suite of products is designed for use in hospitals, clinics, doctor's offices and almost anywhere blood pressure monitoring occurs. Medwave has the required technology clearances to market its technology in the United States, Europe and Asia. Medwave's technology is installed in more than 500 hospitals and clinics worldwide. Medwave trades on the NASDAQ small cap market under the symbol MDWV. For more information, visit http://www.medwave.com .
Statements made in this release that are stated as expectations, plans, anticipations, prospects or future estimates or which otherwise look forward in time are considered "forward-looking statements" and involve a variety of risks and uncertainties, known and unknown, which are likely to affect the actual results. The following factors, among others, as well as factors discussed in Medwave's filings with the SEC, have affected and, in the future, could affect Medwave's actual results: resistance to the acceptance of new medical products, the market acceptance of the Primo(TM) system, the Vasotrac(R) system and other products of Medwave, hospital budgeting cycles, the possibility of adverse or negative results or commentary from clinical researchers or other users or evaluators of Medwave's products, Medwave's success in creating effective distribution channels for its products, Medwave's ability to scale up its manufacturing process, and delays in product development or enhancement or regulatory approval. Consequently, no forward- looking statement can be guaranteed and actual results may vary materially. Medwave(R), Vasotrac(R), Legato(TM), Primo(TM), and Fusion(TM) are trademarks of Medwave, Inc.
Medwave, Inc.CONTACT: Investor Relations, Jodie Chastain, +1-800-894-7601, or MediaRelations, Kevin Sawyer, +1-612-465-8356, both of Medwave, Inc.
